Advertisement

Topics

Silence’s SLN124 gets orphan designation in Europe for β-Thalassemia

05:04 EST 17 Jan 2019 | Pharmaceutical Business Review

The designation to SLN124 was granted by the Committee for Orphan Medicinal Products (COMP), a committee of the European Medicines Agency (EMA). COMP after reviewing an application filed

The post Silence’s SLN124 gets orphan designation in Europe for β-Thalassemia appeared first on Pharmaceutical Business review.

Original Article: Silence’s SLN124 gets orphan designation in Europe for β-Thalassemia

NEXT ARTICLE

More From BioPortfolio on "Silence’s SLN124 gets orphan designation in Europe for β-Thalassemia"

Advertisement
Quick Search
Advertisement
Advertisement